Phase 2 clinical stroke trial on track for completion
An advanced clinical trial assessing the safety of the neuroprotective drug ARG-007 in patients who have experienced acute ischemic stroke...
Continue reading
This website may not work correctly in Internet Explorer. We recommend switching to a more secure modern web browser such as Microsoft Edge which is already installed on your computer.
Research group
Olia is a PhD candidate with a background in chemistry and biochemistry. She is also familiar with different methods of nanoparticle synthesis. Her project focuses on fabricating a nanocarrier that can cross therapeutic agents through the blood-brain barrier, delivering them to the damaged brain cells and releasing them at the target site in Alzheimer’s disease. She hopes to overcome the difficulty in treating brain disorders and remove concerns about increasing their number worldwide.
Keep informed with our latest updates.
Stay up to date with our latest news and announcements.